Top Quality Pharmaceutical Raw Materials Idebenone
Abstract
Product Name: Idebenone
CAS: 58186-27-9
MF: C19H30O5
MW: 338.44
Mol File: 58186-27-9.mol
Executive standard:Enterprise standard
Appearance: Orange yellow or orange crystalline powder, odorless, flavorless.
Property: This product is orange yellow or orange crystalline powder, soluble in methanol, ethanol, insoluble in water, odorless, flavorless.
Used for cerebral infarction, cerebral hemorrhage and cerebral artery sclerosis associated with depression, such as language barriers and intelligence impairment, etc.
Product Description:
Idebenone is a new type of anti-senile dementia medicine and brain function metabolism and mental symptoms improvement medicine. Can improve brain energy metabolism, improve brain function, and mild antihypertensive effect. Clinical for cerebral infarction, cerebral hemorrhage and atherosclerosis sequelae caused brain dysfunction, hypogonadism, emotional disorders, speech disorders, dementia and other patients.
Description:
Chemically, idebenone is an organic compound of the quinone family. It is also promoted commercially as a synthetic analog of coenzyme Q10 (CoQ10). Idebenone (pronounced eye-deb-eh-known, trade names Catena, Raxone, Sovrima, among others) is a drug that was initially developed by Takeda Pharmaceutical Company for the treatment of Alzheimer’s disease and other cognitive defects. This has been met with limited success. The Swiss company Santhera Pharmaceuticals has started to investigate it for the treatment of neuromuscular diseases. In 2010, early clinical trials for the treatment of Friedreich’s ataxia and Duchenne muscular dystrophy have been completed. As of December 2013 the drug is not approved for these indications in North America or Europe, but it is approved for the treatment of Leber’s hereditary optic neuropathy (LHON) in Europe. Nootropic effects and Alzheimer’s disease Idebenone improved learning and memory in experiments with mice. In humans, evaluation of Surrogate endpoints like electroretinography, auditory evoked potentials and visual analogue scales also suggested positive nootropic effects, but larger studies with hard endpoints are missing.
Research on idebenone as a potential therapy of Alzheimer’s disease have been inconsistent, but there may be a trend for a slight benefit. In May 1998, the approval for this indication was cancelled in Japan due to the lack of proven effects. In some European countries, the drug is available for the treatment of individual patients in special cases.
Sales Manager